Clinical outcomes and hemorrhagic or thromboembolic risks in decompressive craniectomy for patients taking antiplatelet or anticoagulant therapy.

IF 2.5 3区 医学 Q2 CLINICAL NEUROLOGY Neurosurgical Review Pub Date : 2025-03-26 DOI:10.1007/s10143-025-03491-4
Alba Scerrati, Giovanni Scanferla, Lorenzo Sgarbanti, Giorgio Mantovani, Chiara Angelini, Maria Elena Flacco, Rosario Maugeri, Lapo Bonosi, Domenico Gerardo Iacopino, Silvana Tumbiolo, Alessandro Adorno, Lara Brunasso, Giorgio Lofrese, Vittoria Rosetti, Luigino Tosatto, Teresa Somma, Luigi Maria Cavallo, Sara Lombardi, Carmelo Lucio Sturiale, Francesco Signorelli, Anna Maria Auricchio, Grazia Menna, Luca Ricciardi, Nicola Montemurro, Fabio Raneri, Oriela Rustemi, Giampaolo Zambon, Michele Alessandro Cavallo, Pasquale De Bonis
{"title":"Clinical outcomes and hemorrhagic or thromboembolic risks in decompressive craniectomy for patients taking antiplatelet or anticoagulant therapy.","authors":"Alba Scerrati, Giovanni Scanferla, Lorenzo Sgarbanti, Giorgio Mantovani, Chiara Angelini, Maria Elena Flacco, Rosario Maugeri, Lapo Bonosi, Domenico Gerardo Iacopino, Silvana Tumbiolo, Alessandro Adorno, Lara Brunasso, Giorgio Lofrese, Vittoria Rosetti, Luigino Tosatto, Teresa Somma, Luigi Maria Cavallo, Sara Lombardi, Carmelo Lucio Sturiale, Francesco Signorelli, Anna Maria Auricchio, Grazia Menna, Luca Ricciardi, Nicola Montemurro, Fabio Raneri, Oriela Rustemi, Giampaolo Zambon, Michele Alessandro Cavallo, Pasquale De Bonis","doi":"10.1007/s10143-025-03491-4","DOIUrl":null,"url":null,"abstract":"<p><p>Decompressive craniectomy (DC) is a critical surgical intervention for elevated intracranial pressure. However, the impact of preoperative antiplatelet or anticoagulant therapy on outcomes and complications remains unclear. A retrospective-prospective study was conducted on 145 patients undergoing DC between November 2021 and May 2023. Patients were categorized into two groups: those with (n = 48) and without (n = 97) preoperative antithrombotic therapy. Demographic data, comorbidities, antithrombotic therapy type and duration, clinical outcomes, and pre-operative risk factors (CHA2DS2-VASc and HAS-BLED scores) were analyzed. While there was a trend towards higher hemorrhagic complications in the antithrombotic therapy group (20.0% vs. 11.3%), this difference was not statistically significant. However, thromboembolic events, primarily stroke (27.7% vs. 9.3%) and acute myocardial infarction (10.6% vs. 0.0%), were significantly more frequent in the antithrombotic therapy group. Multivariate analysis revealed that ischemic stroke as a primary diagnosis, rather than antithrombotic therapy itself, was a significant predictor of thromboembolic complications (adjusted OR 3.49, 95%CI 1.47-8.28, p = 0.005). Pre-operative GCS was associated with improved outcomes (adjusted OR 0.81, 95%CI 0.67-0.97, p = 0.025). While antithrombotic therapy does not appear to increase the risk of hemorrhagic complications after DC, it is associated with a higher risk of thromboembolic events, especially in patients with ischemic stroke. Individualized assessment and tailored management of antithrombotic therapy are crucial to optimize outcomes in DC patients. Further studies are needed to refine strategies for bridging anticoagulation and managing antithrombotic therapy in this population, considering factors such as CHA2DS2-VASc and HAS-BLED scores, as well as patient-specific risk profiles.</p>","PeriodicalId":19184,"journal":{"name":"Neurosurgical Review","volume":"48 1","pages":"328"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947026/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgical Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10143-025-03491-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Decompressive craniectomy (DC) is a critical surgical intervention for elevated intracranial pressure. However, the impact of preoperative antiplatelet or anticoagulant therapy on outcomes and complications remains unclear. A retrospective-prospective study was conducted on 145 patients undergoing DC between November 2021 and May 2023. Patients were categorized into two groups: those with (n = 48) and without (n = 97) preoperative antithrombotic therapy. Demographic data, comorbidities, antithrombotic therapy type and duration, clinical outcomes, and pre-operative risk factors (CHA2DS2-VASc and HAS-BLED scores) were analyzed. While there was a trend towards higher hemorrhagic complications in the antithrombotic therapy group (20.0% vs. 11.3%), this difference was not statistically significant. However, thromboembolic events, primarily stroke (27.7% vs. 9.3%) and acute myocardial infarction (10.6% vs. 0.0%), were significantly more frequent in the antithrombotic therapy group. Multivariate analysis revealed that ischemic stroke as a primary diagnosis, rather than antithrombotic therapy itself, was a significant predictor of thromboembolic complications (adjusted OR 3.49, 95%CI 1.47-8.28, p = 0.005). Pre-operative GCS was associated with improved outcomes (adjusted OR 0.81, 95%CI 0.67-0.97, p = 0.025). While antithrombotic therapy does not appear to increase the risk of hemorrhagic complications after DC, it is associated with a higher risk of thromboembolic events, especially in patients with ischemic stroke. Individualized assessment and tailored management of antithrombotic therapy are crucial to optimize outcomes in DC patients. Further studies are needed to refine strategies for bridging anticoagulation and managing antithrombotic therapy in this population, considering factors such as CHA2DS2-VASc and HAS-BLED scores, as well as patient-specific risk profiles.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
采用抗血小板或抗凝治疗的患者减压颅骨切除术的临床结果和出血或血栓栓塞风险
减压颅骨切除术(DC)是颅内压升高的关键手术干预。然而,术前抗血小板或抗凝治疗对预后和并发症的影响尚不清楚。一项回顾性前瞻性研究在2021年11月至2023年5月期间对145名接受DC治疗的患者进行了研究。患者分为两组:术前抗栓治疗组(n = 48)和未术前抗栓治疗组(n = 97)。分析人口统计学数据、合并症、抗血栓治疗类型和持续时间、临床结局和术前危险因素(CHA2DS2-VASc和HAS-BLED评分)。虽然抗栓治疗组有较高出血性并发症的趋势(20.0% vs 11.3%),但差异无统计学意义。然而,血栓栓塞事件,主要是中风(27.7%对9.3%)和急性心肌梗死(10.6%对0.0%),在抗栓治疗组明显更频繁。多因素分析显示,缺血性脑卒中作为主要诊断,而不是抗栓治疗本身,是血栓栓塞并发症的重要预测因素(调整后OR为3.49,95%CI为1.47-8.28,p = 0.005)。术前GCS与预后改善相关(调整OR 0.81, 95%CI 0.67-0.97, p = 0.025)。虽然抗栓治疗似乎不会增加DC后出血性并发症的风险,但它与血栓栓塞事件的高风险相关,尤其是缺血性卒中患者。个体化评估和量身定制的抗血栓治疗管理是优化DC患者预后的关键。考虑到CHA2DS2-VASc和HAS-BLED评分等因素,以及患者特定的风险概况,需要进一步的研究来完善在这一人群中架桥抗凝和管理抗血栓治疗的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurosurgical Review
Neurosurgical Review 医学-临床神经学
CiteScore
5.60
自引率
7.10%
发文量
191
审稿时长
6-12 weeks
期刊介绍: The goal of Neurosurgical Review is to provide a forum for comprehensive reviews on current issues in neurosurgery. Each issue contains up to three reviews, reflecting all important aspects of one topic (a disease or a surgical approach). Comments by a panel of experts within the same issue complete the topic. By providing comprehensive coverage of one topic per issue, Neurosurgical Review combines the topicality of professional journals with the indepth treatment of a monograph. Original papers of high quality are also welcome.
期刊最新文献
Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis. Temporal patterns of facial nerve palsy after microsurgical resection of vestibular schwannoma: immediate vs. delayed onset, management, and outcomes. Hemorrhagic complications in deep brain stimulation: analysis of non-surgical risk factors in a cohort of 683 patients. Hemodynamic and radiomic parameters of the nidus predict multiple-stage embolizations in brain arteriovenous malformations. A deep learning-based model for postoperative resection assessment in glioblastoma: A comparative study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1